Protagenic Therapeutics Stock Last Dividend Paid
| PTIX Stock | USD 2.69 0.03 1.10% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Protagenic Therapeutics' long-term financial health and intrinsic value.
Protagenic | Last Dividend Paid | Build AI portfolio with Protagenic Stock |
Protagenic Therapeutics Company Last Dividend Paid Analysis
Protagenic Therapeutics' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Protagenic Last Dividend Paid Driver Correlations
Understanding the fundamental principles of building solid financial models for Protagenic Therapeutics is extremely important. It helps to project a fair market value of Protagenic Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since Protagenic Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Protagenic Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Protagenic Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, Protagenic Therapeutics has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Protagenic Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Protagenic Therapeutics from analyzing Protagenic Therapeutics' financial statements. These drivers represent accounts that assess Protagenic Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Protagenic Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 324.2M | 327.8M | 285.6M | 58.9M | 31.8M | 30.2M |
Protagenic Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Protagenic Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Protagenic Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Protagenic Fundamentals
| Return On Equity | -5.13 | ||||
| Return On Asset | -1.9 | ||||
| Current Valuation | (2.49 M) | ||||
| Shares Outstanding | 868.41 K | ||||
| Shares Owned By Insiders | 11.20 % | ||||
| Shares Owned By Institutions | 10.50 % | ||||
| Number Of Shares Shorted | 9.92 K | ||||
| Price To Earning | 9.43 X | ||||
| Price To Book | 1.61 X | ||||
| EBITDA | (5.47 M) | ||||
| Net Income | (5.53 M) | ||||
| Cash And Equivalents | 8.87 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 942.76 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 19.47 X | ||||
| Book Value Per Share | (0.16) X | ||||
| Cash Flow From Operations | (4.22 M) | ||||
| Short Ratio | 0.05 X | ||||
| Earnings Per Share | (13.13) X | ||||
| Target Price | 4.0 | ||||
| Beta | 0.38 | ||||
| Market Capitalization | 2.36 M | ||||
| Total Asset | 1.96 M | ||||
| Retained Earnings | (36.3 M) | ||||
| Working Capital | 940.11 K | ||||
| Current Asset | 3.75 M | ||||
| Current Liabilities | 736 K | ||||
| Net Asset | 1.96 M |
About Protagenic Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protagenic Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protagenic Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protagenic Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.